Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
Номер патента: EP3793583A1
Опубликовано: 24-03-2021
Автор(ы): Jean Gosselin, Serge Rivest
Принадлежит: UNIVERSITE LAVAL
Опубликовано: 24-03-2021
Автор(ы): Jean Gosselin, Serge Rivest
Принадлежит: UNIVERSITE LAVAL
Реферат: Disclosed is a new treatment for reducing amyloid beta (Aβ), for treating Alzheimer's disease (AD), for improvement of cognitive disorder or learning and memory disorder associated with AD and for the treatment of multiple sclerosis. It was found that a NOD2 agonist could improve phagocytosis of Aβ across the blood brain barrier, to be scavenged by increased concentration of patrolling monocytes caused by the NOD2 agonist, removing Aβ from circulation, thereby preventing its eventual deposit. Also disclosed is a composition for such use.
New synthetic drugs for treating alzheimer's disease
Номер патента: WO2024058196A1. Автор: Hiroshi Yamada,Tomoyuki Takahashi,Tetsuya Hori,Zacharie Taoufiq,Kohji TAKEI. Владелец: OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION. Дата публикации: 2024-03-21.